OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice
Raye Z. Litten, Daniel E. Falk, Megan L. Ryan, et al.
Alcoholism Clinical and Experimental Research (2019) Vol. 44, Iss. 1, pp. 23-35
Closed Access | Times Cited: 23
Raye Z. Litten, Daniel E. Falk, Megan L. Ryan, et al.
Alcoholism Clinical and Experimental Research (2019) Vol. 44, Iss. 1, pp. 23-35
Closed Access | Times Cited: 23
Showing 23 citing articles:
Immune treatments for alcohol use disorder: A translational framework
Lindsay R. Meredith, Elizabeth M. Burnette, Erica N. Grodin, et al.
Brain Behavior and Immunity (2021) Vol. 97, pp. 349-364
Open Access | Times Cited: 41
Lindsay R. Meredith, Elizabeth M. Burnette, Erica N. Grodin, et al.
Brain Behavior and Immunity (2021) Vol. 97, pp. 349-364
Open Access | Times Cited: 41
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2132-2139
Open Access | Times Cited: 35
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2132-2139
Open Access | Times Cited: 35
Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders
Michael P. Bremmer, Christian S. Hendershot
Journal of Studies on Alcohol and Drugs (2023)
Closed Access | Times Cited: 14
Michael P. Bremmer, Christian S. Hendershot
Journal of Studies on Alcohol and Drugs (2023)
Closed Access | Times Cited: 14
New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies
Kirsten C. Morley, Christina J. Perry, Joshua Watt, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1291-1303
Closed Access | Times Cited: 32
Kirsten C. Morley, Christina J. Perry, Joshua Watt, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1291-1303
Closed Access | Times Cited: 32
Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder
Falk W. Lohoff
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 18
Falk W. Lohoff
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 18
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
Ming‐Fen Ho, Cheng Zhang, Lixuan Wei, et al.
British Journal of Pharmacology (2022) Vol. 179, Iss. 13, pp. 3330-3345
Open Access | Times Cited: 14
Ming‐Fen Ho, Cheng Zhang, Lixuan Wei, et al.
British Journal of Pharmacology (2022) Vol. 179, Iss. 13, pp. 3330-3345
Open Access | Times Cited: 14
Targeting muscarinic receptors for the treatment of alcohol use disorders: opportunities and hurdles for clinical development
Leigh C. Walker, Kade L. Huckstep, Howard C. Becker, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 22, pp. 4385-4398
Open Access | Times Cited: 8
Leigh C. Walker, Kade L. Huckstep, Howard C. Becker, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 22, pp. 4385-4398
Open Access | Times Cited: 8
Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy
Steven J. Nieto, Han Du, Lindsay R. Meredith, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1679-1689
Open Access | Times Cited: 2
Steven J. Nieto, Han Du, Lindsay R. Meredith, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1679-1689
Open Access | Times Cited: 2
Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder
Lara A. Ray, Han Du, ReJoyce Green, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 3, pp. 519-527
Open Access | Times Cited: 18
Lara A. Ray, Han Du, ReJoyce Green, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 3, pp. 519-527
Open Access | Times Cited: 18
Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study
Erica N. Grodin, Lindsay R. Meredith, Elizabeth M. Burnette, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 49, Iss. 3, pp. 333-344
Open Access | Times Cited: 9
Erica N. Grodin, Lindsay R. Meredith, Elizabeth M. Burnette, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 49, Iss. 3, pp. 333-344
Open Access | Times Cited: 9
IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study
Ming‐Fen Ho, Cheng Zhang, James S. Cohan, et al.
Brain Behavior and Immunity (2024) Vol. 120, pp. 304-314
Open Access | Times Cited: 1
Ming‐Fen Ho, Cheng Zhang, James S. Cohan, et al.
Brain Behavior and Immunity (2024) Vol. 120, pp. 304-314
Open Access | Times Cited: 1
Prefrontal electrophysiological biomarkers and mechanism-based drug effects in a rat model of alcohol addiction
Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Medication Development For Aud: A Systematic Review Of Clinical Trial Methodology
Stefano Di Donato, Lindsay R. Meredith, Steven J. Nieto, et al.
Alcohol (2024) Vol. 120, pp. 194-203
Closed Access | Times Cited: 1
Stefano Di Donato, Lindsay R. Meredith, Steven J. Nieto, et al.
Alcohol (2024) Vol. 120, pp. 194-203
Closed Access | Times Cited: 1
The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter
Lorenzo Leggio, Raye Z. Litten
Neuropsychopharmacology (2021) Vol. 46, Iss. 13, pp. 2228-2229
Open Access | Times Cited: 10
Lorenzo Leggio, Raye Z. Litten
Neuropsychopharmacology (2021) Vol. 46, Iss. 13, pp. 2228-2229
Open Access | Times Cited: 10
Are medication effects on subjective response to alcohol and cue-induced craving associated? A meta regression study
Lara A. Ray, Steven J. Nieto, Lindsay R. Meredith, et al.
Psychopharmacology (2023) Vol. 240, Iss. 9, pp. 1921-1930
Open Access | Times Cited: 3
Lara A. Ray, Steven J. Nieto, Lindsay R. Meredith, et al.
Psychopharmacology (2023) Vol. 240, Iss. 9, pp. 1921-1930
Open Access | Times Cited: 3
Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation
Ming‐Fen Ho, Cheng Zhang, Irene Moon, et al.
Molecular Metabolism (2023) Vol. 77, pp. 101798-101798
Open Access | Times Cited: 2
Ming‐Fen Ho, Cheng Zhang, Irene Moon, et al.
Molecular Metabolism (2023) Vol. 77, pp. 101798-101798
Open Access | Times Cited: 2
Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol Addiction
Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz, et al.
Research Square (Research Square) (2024)
Open Access
Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz, et al.
Research Square (Research Square) (2024)
Open Access
Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial
Tracy L. Simpson, Carol E. Achtmeyer, Lisa Batten, et al.
Alcohol and Alcoholism (2024) Vol. 59, Iss. 5
Closed Access
Tracy L. Simpson, Carol E. Achtmeyer, Lisa Batten, et al.
Alcohol and Alcoholism (2024) Vol. 59, Iss. 5
Closed Access
Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics Study
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 3
Joanna M. Biernacka, Brandon J. Coombes, Anthony Batzler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 3
A meta‐regression of methodological features that predict the effects of medications on the subjective response to alcohol
ReJoyce Green, Han Du, Erica N. Grodin, et al.
Alcoholism Clinical and Experimental Research (2021) Vol. 45, Iss. 7, pp. 1336-1347
Open Access | Times Cited: 2
ReJoyce Green, Han Du, Erica N. Grodin, et al.
Alcoholism Clinical and Experimental Research (2021) Vol. 45, Iss. 7, pp. 1336-1347
Open Access | Times Cited: 2
Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder
András H. Lékó, Mehdi Farokhnia, Lorenzo Leggio
Springer eBooks (2023), pp. 261-288
Closed Access
András H. Lékó, Mehdi Farokhnia, Lorenzo Leggio
Springer eBooks (2023), pp. 261-288
Closed Access
Brain-Immune Mechanisms in Alcohol Use Disorder Targeting Neuroimmune Signaling in Alcohol Use Disorder: Opportunities for Translation
Erica N. Grodin, Lindsay R. Meredith, Elizabeth M. Burnette, et al.
Springer eBooks (2023), pp. 551-573
Closed Access
Erica N. Grodin, Lindsay R. Meredith, Elizabeth M. Burnette, et al.
Springer eBooks (2023), pp. 551-573
Closed Access
Alcohol Use Disorder and the Gut Microbiome
Khushboo Gala, Evan Winrich, Saurabh Kumar Jha, et al.
Current Addiction Reports (2023) Vol. 11, Iss. 1, pp. 105-112
Closed Access
Khushboo Gala, Evan Winrich, Saurabh Kumar Jha, et al.
Current Addiction Reports (2023) Vol. 11, Iss. 1, pp. 105-112
Closed Access
